Literature DB >> 10522872

Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France.

J Huillard d'Aignaux1, D Costagliola, J Maccario, T Billette de Villemeur, J P Brandel, J P Deslys, J J Hauw, J L Chaussain, Y Agid, D Dormont, A Alpérovitch.   

Abstract

OBJECTIVE: To estimate the statistical distribution of the incubation period of Creutzfeldt-Jakob disease (CJD) in human growth hormone (hGH) recipients in France.
BACKGROUND: Published papers suggest that the median incubation period of hGH-related CJD is approximately 15 years, but there are as yet no statistical data that support this assertion.
METHODS: Of the 1,361 hGH recipients who were included in this study, 55 had developed CJD at the time of the study. Individual data on hGH treatment history were available. Different mathematical models were used to estimate the statistical distribution of the incubation period. One main feature of the models was to take into account the occurrence of future CJD cases.
RESULTS: Models showed that the mean incubation period was 9 to 10 years, and the 95th percentile of the distribution was 15 to 16 years. Data and models indicated that the incubation period was significantly shorter in homozygotes at codon 129 of the prion protein gene than in heterozygotes.
CONCLUSIONS: The short mean incubation period of CJD in French hGH recipients may be due to high infectivity in hormone lots. Estimates of the 95th percentile indicate that the number of hGH-related CJD cases may continue to increase in the coming years.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10522872     DOI: 10.1212/wnl.53.6.1197

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Identification of multiple quantitative trait loci linked to prion disease incubation period in mice.

Authors:  S E Lloyd; O N Onwuazor; J A Beck; G Mallinson; M Farrall; P Targonski; J Collinge; E M Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

Review 2.  Molecular neurology of prion disease.

Authors:  J Collinge
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-07       Impact factor: 10.154

3.  Factors determining the pattern of the variant Creutzfeldt-Jakob disease (vCJD) epidemic in the UK.

Authors:  Azra C Ghani; Neil M Ferguson; Christl A Donnelly; Roy M Anderson
Journal:  Proc Biol Sci       Date:  2003-04-07       Impact factor: 5.349

4.  MRI and clinical syndrome in dura mater-related Creutzfeldt-Jakob disease.

Authors:  B Meissner; K Kallenberg; P Sanchez-Juan; S Ramljak; A Krasnianski; U Heinemann; S Eigenbrod; E Gelpi; B Barsic; H A Kretzschmar; W J Schulz-Schaeffer; M Knauth; I Zerr
Journal:  J Neurol       Date:  2009-01-23       Impact factor: 4.849

5.  Dominant prion mutants induce curing through pathways that promote chaperone-mediated disaggregation.

Authors:  Susanne DiSalvo; Aaron Derdowski; John A Pezza; Tricia R Serio
Journal:  Nat Struct Mol Biol       Date:  2011-03-20       Impact factor: 15.369

6.  Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns.

Authors:  P Brown; R G Will; R Bradley; D M Asher; L Detwiler
Journal:  Emerg Infect Dis       Date:  2001 Jan-Feb       Impact factor: 6.883

7.  Updated projections of future vCJD deaths in the UK.

Authors:  Azra C Ghani; Christl A Donnelly; Neil M Ferguson; Roy M Anderson
Journal:  BMC Infect Dis       Date:  2003-04-27       Impact factor: 3.090

8.  A dose and time response Markov model for the in-host dynamics of infection with intracellular bacteria following inhalation: with application to Francisella tularensis.

Authors:  R M Wood; J R Egan; I M Hall
Journal:  J R Soc Interface       Date:  2014-06-06       Impact factor: 4.118

9.  Prion protein expression and processing in human mononuclear cells: the impact of the codon 129 prion gene polymorphism.

Authors:  Christiane Segarra; Sylvain Lehmann; Joliette Coste
Journal:  PLoS One       Date:  2009-06-04       Impact factor: 3.240

10.  Risk assessment of transmission of sporadic Creutzfeldt-Jakob disease in endodontic practice in absence of adequate prion inactivation.

Authors:  Nadège Bourvis; Pierre-Yves Boelle; Jean-Yves Cesbron; Alain-Jacques Valleron
Journal:  PLoS One       Date:  2007-12-26       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.